Immunotherapy drug nivolumab takes on rare childhood cancer
NCT ID NCT06622941
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This phase 2 trial is testing the immunotherapy drug nivolumab in 23 people aged 1 year and older with advanced or recurrent rhabdoid tumors that have not responded to chemotherapy. The goal is to see if the drug can shrink tumors and improve survival. Participants receive nivolumab every two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nivolumab (a type of immunotherapy that helps the immune system fight cancer)
- What this could lead to
- If it works, this could offer a new treatment option for people with rhabdoid tumors that have not responded to chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chiba University Hospital
RECRUITINGChiba, Japan
-
Fukushima Medical University Hospital
RECRUITINGFukushima, Japan
-
Hiroshima University Hospital
RECRUITINGHiroshima, Japan
-
Hokkaido University Hospital
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Hyogo Prefectural Kobe Children's Hospital
RECRUITINGKobe, Hyōgo, Japan
-
Kanazawa University Hospital
RECRUITINGKanazawa, Japan
-
Kyushu University Hospital
NOT_YET_RECRUITINGFukuoka, Japan
-
Nagoya University Hospital
RECRUITINGNagoya, Aichi-ken, Japan
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, Japan
-
National Center for Child Health and Development
RECRUITINGTokyo, Japan
-
Niigata University Medical & Dental Hospital
RECRUITINGNiigata, Japan
-
Osaka City General Hospital
RECRUITINGOsaka, Osaka, Japan
-
Tohoku University Hospital
RECRUITINGMiyagi, Japan
-
University Hospital, Kyoto Prefectural University of Medicine
RECRUITINGKyoto, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted radiation zaps childhood brain tumors in early trial
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New drug targets tough childhood cancers with genetic flaws
- New stem cell transplant shows promise for kids with tough cancers
- Engineered immune cells take aim at childhood cancers in early trial
- Protein map of rare childhood cancer could reveal new attack points